Cover Image
市場調查報告書

肺動脈高血壓 (PAH)的全球市場 (各類藥物,各地區,各國):機會及預測

Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts 2016-2021

出版商 Azoth Analytics 商品編碼 367318
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
肺動脈高血壓 (PAH)的全球市場 (各類藥物,各地區,各國):機會及預測 Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts 2016-2021
出版日期: 2016年08月16日 內容資訊: 英文 140 Pages
簡介

本報告提供肺動脈高血壓 (以下PAH)的治療藥的市場相關分析,關於PAH的特徵和主要的治療方法,全球整體及各類藥物的市場規模趨勢 (總計11年份),各地區及主要國家 (共7個國家)的詳細趨勢,法規環境,競爭力,資本交易、市場競爭的動向,主要企業簡介等調查評估。

第1章 分析方法

第2章 摘要整理

第3章 策略性建議

  • PAH市場今後預計緩慢地成長
  • ERA促進PAH市場
  • 佔北美、歐洲市場大部分

第4章 全球PAH市場:概要

  • 產品概要
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)
    • 各類藥物的市場規模 (以金額為準,今後6年份)
  • 全球內皮素受體拮抗劑 (ERA) 市場
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)
  • 全球前列腺環素、類似物市場
  • 全球磷酸二酯酶 (PDE) V抑制劑市場
  • 其他的醫藥品的市場
  • PAH治療藥的開發平台分析

第5章 北美的PAH市場:概要

  • 地區市場
    • 市場規模的成果值 (以金額為準,過去5年份)
    • 市場規模的預測值 (以金額為準,今後6年份)
  • 各國市場:美國,加拿大

第6章 歐洲的PAH市場:概要

  • 地區市場
  • 各國市場:英國,德國

第7章 亞太地區的PAH市場:概要

  • 地區市場
  • 各國市場:日本

第8章 南美的PAH市場:概要

  • 地區市場
  • 各國市場:巴西

第9章 中東、非洲的PAH市場:概要

  • 地區市場
  • 各國市場:南非

第10章 市場動態

  • 市場趨勢和動靜
  • 推動因素
  • 課題

第11章 政策、法規環境

第12章 PAH市場上企業合併、收購 (M&A)/授權合約的途徑

第13章 SWOT分析

第14章 波特的五力分析、模式

第15章 各企業市場佔有率分析

第16章 競爭環境

第17章 企業簡介

  • Actelion Pharmaceuticals Ltd.
  • United Therapeutics Corporation
  • Gilead sciences
  • Bayer AG
  • SteadyMed Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Reata Pharmaceuticals Inc.
  • Arena Pharmaceuticals Inc.
  • Merck & Co. Inc

第18章 Azoth Analytics相關資料,免責聲明

圖表一覽

目錄

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).

The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.

Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 - 2021F, on account of rising prevalence of the PAH disease among the population.

North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.

According to Azoth Analytics research report, ‘Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021)’, Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)

Scope of the Report

The report provides Segmentation by Drug Class

  • Endothelin receptor antagonists
  • Prostacyclin and Prostacyclin Analogs
  • Phosphodiesterase V Inhibitors
  • Others

The report provides coverage by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

The report provides coverage by Country

  • USA
  • Canada
  • UK
  • Germany
  • Japan
  • Brazil
  • South Africa

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

  • 3.1. PAH Market to Grow at a Moderate Rate
  • 3.2. ERA to the Drive the PAH Market
  • 3.3. PAH Market to be Dominated by North America and Europe

4. Global PAH Market: An Overview

  • 4.1. Product Overview
    • 4.1.1. Global PAH Market, By Value 2011-2015
    • 4.1.2. Global PAH Market, By Value 2016-2021F
    • 4.1.3 Global PAH Market: By Drug Class Type, By Value (2016E-2021F)
      • Global PAH Market: By Type (Endothelin receptor antagonists, Prostacyclin and Prostacyclin Analogs, Phosphodiesterase V Inhibitors and others)
  • 4.2. Global Endothelin Receptor Antagonist Market
    • 4.2.1. By Value (Historic 2011-15)
    • 4.2.2. By Value (Forecast 2016E-2021F)
  • 4.3. Global Prostacyclin and Prostacyclin Analogs Market
    • 4.3.1.By Value (Historic 2011-15)
    • 4.3.2.By Value (Forecast 2016E-2021F)
  • 4.4. Global Phosphodiesterase V Inhibitors Market
    • 4.4.1.By Value (Historic 2011-15)
    • 4.4.2.By Value (Forecast 2016E-2021F)
  • 4.5. Global Other Drugs Market
    • 4.5.1. By Value (Historic 2011-15)
    • 4.5.2. By Value (Forecast 2016E-2021F)
  • 4.6. PAH Drugs Pipeline Analysis

5. North America PAH Market: An Overview

  • 5.1. North America PAH Market
    • 5.1.1. By Value (Historic 2011-15)
    • 5.1.2. By Value (Forecast 2016E-2021F)
  • 5.2. North America PAH Country Market - USA, Canada

6. Europe PAH Market: An Overview

  • 6.1. Europe PAH Market
    • 6.1.1. By Value (Historic 2011-15)
    • 6.1.2. By Value (Forecast 2016E-2021F)
  • 6.2. Europe PAH Country Overview - UK, Germany

7. APAC PAH Market: An Overview

  • 7.1. APAC PAH Market
    • 7.1.1. By Value (Historic 2011-15)
    • 7.1.2. By Value (Forecast 2016E-2021F)
  • 7.2. APAC PAH Country Overview - Japan

8. Latin America PAH Market: An Overview

  • 8.1. Latin America PAH Market
    • 8.1.1. By Value (Historic 2011-15)
    • 8.1.2. By Value (Forecast 2016E-2021F)
  • 8.2. Latin America PAH Country Overview - Brazil

9. MEA PAH Market: An Overview

  • 9.1. MEA PAH Market
    • 9.1.1. By Value (Historic 2011-15)
    • 9.1.2. By Value (Forecast 2016E-2021F)
  • 9.2. MEA PAH Country Overview - South Africa

10. Market Dynamics

  • 10.1. Market Trends & Developments
  • 10.2. Drivers
  • 10.3. Challenges

11. Policy and Regulatory Landscape

12. M&A and Licensing Route to the PAH Market

13. SWOT Analysis

14. Porter Five Force Model

15. Competitive Market Share Analysis

16. Competitive landscape

17. Company Profiling

  • 17.1. Actelion Pharmaceuticals Ltd.
  • 17.2. United Therapeutics Corporation
  • 17.3. Gilead sciences
  • 17.4. Bayer AG
  • 17.5. SteadyMed Ltd.
  • 17.6. GlaxoSmithKline plc
  • 17.7. Pfizer Inc.
  • 17.8. Reata Pharmaceuticals Inc.
  • 17.9. Arena Pharmaceuticals Inc.
  • 17.10. Merck & Co. Inc

18. About us & Disclaimer

List of Figure

  • Figure 1: Global PAH Market, 2011-2015 (USD Billion)
  • Figure 2: Types of pulmonary arterial hypertension
  • Figure 3: PAH Associated With Other Diseases (APAH)
  • Figure 4: Global PAH Market, 2016E-2021F (USD Billion)
  • Figure 5: Global PAH Market: By Drug Class Type, By Value, 2016E (In Percentage)
  • Figure 6: Global PAH Market: By Drug Class Type, By Value, 2021F (In Percentage)
  • Figure 7: Global PAH Market: By ERA, By Value, 2011-2021F (in USD Billion)
  • Figure 8: Global PAH Market: By Prostacyclin and Prostacyclin Analogs, By Value, 2011-2021F (in USD Billion)
  • Figure 9: Global PAH Market: By Phosphodiesterase V Inhibitors, By Value, 2011-2021F (in USD Million)
  • Figure 10: Global PAH Market: By Others, By Value, 2011-2021F (in USD Million)
  • Figure 11: North America PAH Market, 2011-2015 (USD Billion)
  • Figure 12: North America PAH Market, 2016E- 2021F (USD Billion)
  • Figure 13: USA PAH Market Size, By Value, 2011-2021F (in USD Billion)
  • Figure 14: Estimated Number of Cases of PAH in USA
  • Figure 15: Canada PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 16: Estimated Number of Cases of PAH in Canada
  • Figure 17: Europe PAH Market, 2011-2015 (USD Billion)
  • Figure 18: Europe PAH Market, 2016E- 2021F (USD Billion)
  • Figure 19: UK PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 20: Germany PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 21: Estimated Number of Cases of PAH in Germany
  • Figure 22: APAC PAH Market, 2011-2015 (USD Million)
  • Figure 23: APAC PAH Market, 2016E - 2021F (USD Million)
  • Figure 24: Japan PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 25: Estimated Number of Cases of PAH in Japan
  • Figure 26: Latin America PAH Market, 2011-2015 (USD Million)
  • Figure 27: Latin America PAH Market, 2016E- 2021F (USD Million)
  • Figure 28: Brazil PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 29: Estimated Number of Cases of PAH in Brazil
  • Figure 30: MEA PAH Market, 2011-2015 (USD Million)
  • Figure 31: MEA PAH Market, 2016E- 2021F (USD Million)
  • Figure 32: South Africa PAH Market Size, By Value, 2011-2021F (in USD Million)
  • Figure 33: Estimated Number of Cases of PAH in South Africa
  • Figure 34: Global PAH Landscape - Market Share (2015)

List of Tables

  • Table 1: Prostacylin - Pipeline Drugs
  • Table 2: ERA - Pipeline Drugs
  • Table 3: PDA 5 Inhibitor - Pipeline Drugs
  • Table 4: PAH - Pipeline Drugs (Phase I & II)
  • Table 5: PAH - Pipeline Drugs (Phase III)
  • Table 6: Mergers and Acquisitions in PAH Market
  • Table 7: Licensing Agreements in PAH Market
  • Table 8: PAH Competitive Landscape: Product Benchmarking
  • Table 9: Actelion -Sales: 2013-2015
  • Table 10: United Therapeutics -Sales: 2013-2015
  • Table 11: Gilead Sciences -Sales: 2013-2015
  • Table 12: Pfizer-Revatio -Sales: 2013-2015
Back to Top